Close Menu

NEW YORK — ZPredicta said on Thursday that it has partnered with Laboratory Corporation of America to develop and commercialize tumor-specific preclinical models based on its 3D cell culture platform.

ZPredicta's platform integrates organ-specific cellular and extracellular elements into 3D culture models for in vitro cancer drug testing. The San Jose, California-based company said that the alliance with LabCorp will help expand the platform's use for preclinical testing and research studies.

Specific terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.